Literature DB >> 18400840

Intrauterine devices and intrauterine systems.

.   

Abstract

From a public health viewpoint, the intrauterine device (IUD) is the most widely used contraceptive method in the world. Prevalence rates range among countries from 2 to 80% of contraceptive users. During 5 years of IUD use, pregnancy occurs in less than 2 per 100 insertions. Bleeding and pain are the most common reasons for removal rates of 10% in the first year and up to 50% within 5 years. The contraceptive effects of IUDs may be due to a sterile inflammatory reaction in the endometrial cavity which interferes with sperm function, so that fertilization is less likely to occur. IUDs also interfere with implantation but the extent to which this contributes to their contraceptive action is unknown. In nulliparous women rates of expulsion and removal for bleeding and/or pain are higher than in parous women. Effective use of IUDs for up to 10 years has the same pregnancy rate as tubal interruption. Thus, the IUD may be an alternative to female sterilization, especially in younger women who are more likely to experience regret after sterilization. The levonorgestrel intrauterine system (LNG-IUS) reduces bleeding and dysmenorrhoea, provides superior effectiveness to copper IUDs, and may be a useful treatment for endometriosis or an alternative to hysterectomy for menorrhagia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400840     DOI: 10.1093/humupd/dmn003

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  26 in total

1.  An approach to give prospective life-span of the copper/low-density-polyethylene nanocomposite intrauterine device.

Authors:  Xianping Xia; Ying Tang; Changsheng Xie; Yun Wang; Shuizhou Cai; Changhong Zhu
Journal:  J Mater Sci Mater Med       Date:  2011-05-21       Impact factor: 3.896

2.  Discontinuation rates and acceptability during 1 year of using the intrauterine ball (the SCu380A).

Authors:  Ellen Wiebe; James Trussell
Journal:  Contraception       Date:  2015-12-08       Impact factor: 3.375

Review 3.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

4.  Systematic Review of Postfertilization Effects and Potential for Embryo Formation and Loss during the Use of Intrauterine Devices.

Authors:  Cara Buskmiller; Donna Harrison; Lester A Ruppersberger; Patrick P Yeung
Journal:  Linacre Q       Date:  2019-06-27

5.  The wandering Mirena: laparoscopic retrieval.

Authors:  Mark Erian; Glenda McLaren; David Baartz
Journal:  JSLS       Date:  2011 Jan-Mar       Impact factor: 2.172

6.  Study of cu T utilization status and some of the factors associated with discontinuation of cu T in rural part of yavatmal district.

Authors:  Nn Ambadekar; Kz Rathod; Sp Zodpey
Journal:  Indian J Community Med       Date:  2011-01

7.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

8.  The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.

Authors:  Megan N Beatty; Paul D Blumenthal
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

9.  Determinants of intrauterine contraceptive device utilization at primary health care facilities in Mekelle City, northern Ethiopia.

Authors:  Gebremaryam Temesgen Birgoda; Haftom Gebrehiwot; Sultan Hussen Hebo; Birhane Hagos; Genet Assefa; Negussie Boti Sidamo; Mulugeta Shegaze Shembri
Journal:  Contracept Reprod Med       Date:  2021-07-01

10.  Comparing the effectiveness of copper intrauterine devices available in Canada. Is FlexiT non-inferior to NovaT when inserted immediately after first-trimester abortion? Study protocol for a randomized controlled trial.

Authors:  Wendy V Norman; Jessica L Chiles; Caroline A Turner; Rollin Brant; Andra Aslan; Janusz Kaczorowski
Journal:  Trials       Date:  2012-08-24       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.